A B S T R A C T
Background. Hemodialysis (HD) patients have an increased risk of thrombosis. Endothelial progenitor cells (EPCs), which function in vascular repair, are deficient in HD patients. Nonetheless, the relationship between EPC deficiency and thrombosis in HD patients is unknown. Methods. From January 2010 to December 2012, circulating levels of EPCs that were positive for CD34 and kinase insert domain receptor (KDR) were measured in 269 HD patients. Patients received prospective follow-ups at 6-month intervals until May 2015. The primary outcome was the composite of HD access thrombosis and systemic vascular thrombosis.
Results. There were 141 thrombotic events, 50 systemic vascular thrombotic events and 116 HD access thrombotic events. We found significantly negative associations between CD34 þ KDR þ tertile and overall thrombotic events (low: 61%; middle: 56%; high: 40%; P ¼ 0.02), systemic vascular thrombotic events (low: 27%; middle: 18%; high: 10%; P ¼ 0.03) and HD access thrombotic events (low: 52%; middle: 46%; high: 36%; P ¼ 0.02). Univariate analysis indicated that systemic vascular thrombotic events were positively associated with age, diabetes, dyslipidemia, vascular disease history, urea clearance, albumin and C-reactive protein (CRP), and negatively associated with CD34 þ KDR þ cell count. HD access thrombosis was positively associated with vascular disease history and CRP, and negatively associated with CD34 þ KDR þ cell count. Multivariate analysis indicated that a low CD34 þ KDR þ cell count was an independent risk factor for both types of thrombosis.
Conclusions. Our study of a population of HD patients showed that a low level of circulating EPCs is associated with thrombosis.
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I N T R O D U C T I O N
Patients with end-stage renal disease (ESRD) have an increased risk for vascular thrombosis. Relative to the general population, ESRD patients have an 8-to 20-fold increased risk of mortality from cardiovascular events [1, 2] . Among the complications of vascular disease, thrombosis is usually a late-occurring event, but it has serious sequelae for ESRD patients [3] . Previous studies reported an increased risk of myocardial infarction, ischemic stroke, acute limb ischemia and deep vein thrombosis in ESRD patients [3] [4] [5] [6] [7] [8] . Creation of a dialysis access (arteriovenous fistula or graft) is associated with frequent stenosis and thrombotic complications [9, 10] . Several metabolic and hematologic alterations in hemodialysis (HD) patients may promote thrombosis [3] . Furthermore, ESRD and atherosclerosis share many risk factors, including traditional (e.g. diabetes mellitus, dyslipidemia and hypertension) and non-traditional (e.g. hyperhomocysteinemia, endothelial dysfunction and inflammation) factors. However, the presence of these factors does not fully explain the extent of vascular disease and the severity of thrombotic events encountered in ESRD.
Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Maintenance of endothelial integrity and function plays a pivotal role in the prevention of atherosclerosis and thrombosis. A growing body of evidence favors the hypothesis that bone marrow-derived endothelial progenitor cells (EPCs) migrate toward sites of endothelial injury and restore vascular function [11] . The number of circulating EPCs reflects vascular repair capacity and correlates with vascular function [12] . In the presence of renal failure, the number and function of EPCs are lower [13, 14] . In ESRD patients, however, findings regarding the interrelationships of EPCs with various vascular changes, including endothelial dysfunction, vascular calcification and specific clinical disorders, are inconsistent [14, 15] . Moreover, very few prospective studies have had sufficient durations of follow-up for clinical events [16] .
The aim of the present study was to examine the relationship between EPC count and thrombosis in a prospective cohort of HD patients.
M A T E R I A L S A N D M E T H O D S

Study participants and protocols
We studied ESRD patients undergoing maintenance HD at six HD centers. All enrolled patients received maintenance HD by arteriovenous fistulas or grafts, three times per week for more than 6 months, and agreed to participate. Patients with the following characteristics were excluded: (i) acute or chronic inflammatory disease, decompensated heart failure, myocardial infarction, acute limb ischemia or stroke requiring hospitalization during the previous 3 months; and (ii) an event of thrombosis at the dialysis access during the previous 3 months (Figure 1 ).
Clinical and access data were obtained from review of medical records, HD records and angiography/angioplasty reports. All eligible patients received 4 h of HD three times weekly using synthetic dialysis membranes (polyamide or polysulfone). The dialysate for all patients had a standard ion composition in a bicarbonate-based buffer, and dialyzers were not reused. The adequacy of dialysis was evaluated monthly using the single pool Kt/V of urea nitrogen. This study was performed in accordance with the Declaration of Helsinki (Edition 6, revised in 2000). All study participants provided written informed consent, and the Institutional Review Board of our institute approved the study.
Laboratory methods
Blood samples were drawn during mid-week on a nondialysis day after a 12-h overnight fast and cessation of medications. Plasma biochemical parameters, including cholesterol, calcium, phosphate and albumin, were determined by standard laboratory procedures. The single-pool Kt/V of urea nitrogen was calculated after enrollment using the second-generation logarithmic formula of Daugirdas. Commercially available kits were used to measure plasma high-sensitivity C-reactive protein (hs-CRP) (Dade Behring, Marburg, Germany) and homocysteine (Axis Homocysteine EIA; Axis-Shield AS, Oslo, Norway).
Flow cytometry was used to measure the circulating level of EPCs, and was performed by researchers who were blinded to all clinical data (Figure 2 ). For this test, peripheral blood (1.0 mL) was pretreated for 30 min in the dark with an allophycocyanin-conjugated monoclonal antibody against human kinase insert domain receptor (KDR; R&D, Minneapolis, MN, USA), a phycoerythrin-conjugated monoclonal antibody against human CD133 (Miltenyi Biotec, Bergisch Gladbach, Germany) and a fluorescein isothiocyanateconjugated monoclonal antibody against human CD34 (Becton Dickinson Pharmingen, NJ, USA) [17] . The cells were then lysed, washed with phosphate-buffered saline and fixed in 2% paraformaldehyde before analysis. Each analysis is from 150 000 acquired events, which was as reliable as 500 000 events (intraclass correlation coefficient >0.95). The viability of EPCs in these profiles was up to 96.3% when viability markers were included. The cell count is expressed as EPCs per 10 5 mononuclear cells. To assess the reproducibility of these findings, EPC measurements were performed on two separate samples obtained from 10 different subjects. There were strong correlations between these two measurements among all subjects (r ¼ 0.90, P < 0.001). Intra-individual variability in the counts of CD34
þ cells over time was assessed in 21 patients by two measurements that were 1 year apart, and the resulting intraclass correlation coefficients were 0.69, 0.75 and 0.78, respectively.
Follow-up
All patients received prospective follow-ups at 6-month intervals by a coordinating study nurse. The follow-up findings were obtained via telephone contact with the referring HD centers. Clinical events, including cardiovascular events and death from various causes, were identified by review of medical records. Dialysis access events were identified by review of dialysis records or angiography/angioplasty reports. All events were coded by a physician who was blinded to the measured biomarkers. If there was doubt about an event, the diagnosis was confirmed through discussion of the coding physicians with the referring nephrologist or the attending physician. 
Outcome definitions
The primary outcome was a composite of systemic vascular thrombotic events and HD vascular access thrombotic events. An HD vascular access thrombotic event was defined as the sudden cessation of flow, rendering HD impossible and requiring thrombectomy or placement of another HD access. A systemic vascular thrombotic event was defined as occurrence of coronary thrombosis, cerebral thrombosis, peripheral arterial thrombosis, deep vein thrombosis or pulmonary embolism that required hospitalization. Coronary thrombosis was diagnosed based on elevation of cardiac enzymes, with or without typical electrocardiographic changes or coronary intervention. Cerebral arterial thrombosis was defined as ischemic stroke with neurological deficit lasting more than 24 h, with confirmation by computed tomography (CT) or magnetic resonance imaging. Peripheral arterial thrombosis was defined as acute ischemia of the limb arteries. Deep venous thrombosis was confirmed by compression ultrasound, and pulmonary embolism was confirmed by contrast CT. Cardiovascular death included death due to myocardial infarction, heart failure, ischemic stroke or sudden cardiac death. The secondary outcomes were death and cardiovascular death. Cases of unobserved sudden death were considered cardiac deaths only when other potential causes could be excluded. Vascular disease history was defined as previous coronary artery disease, cerebral vascular disease or peripheral arterial disease.
Statistical analyses
Continuous variables are presented as means 6 standard deviations (SDs) for normally distributed data and as medians and interquartile ranges (IQRs) for non-normally distributed data. Categorical variables are presented as percentages, and were compared using the chi-square test with Yates' correction or Fisher's exact test, as appropriate. For normally distributed data, the means of groups were compared by a one-way analysis-of-variance. For non-normally distributed data, the Kruskal-Wallis test was used to compare groups. The proportions of patients with thrombosis or death were compared using the chi-square test. Thrombosis-free survival was estimated by the Kaplan-Meier method, and the significance of differences was determined using the log-rank test. The Cox proportional hazard model was used for univariate analysis of predictors of thrombosis. All variables with P-values <0.1 in this univariate analysis were entered into a multivariate analysis. A P-value <0.05 was considered statistically significant. All statistical 
analyses were performed using SPSS software (version 20.0) for Microsoft Windows.
R E S U L T S
Baseline observations
We prospectively enrolled 295 HD patients from January 2010 to December 2012, but excluded 26 of these patients due to the presence of acute coronary syndrome, decompensated heart failure or another recent acute illness. The final study group of 269 patients had a mean age of 69 years (SD: 12 years) and a median dialysis duration of 47 months (IQR: 24-83 months). Left arm accesses were present in 243 patients, and upper arm accesses in 56 patients. The median shunt age was 36 months (IQR: 23-74 months). Table 1 shows the baseline characteristics of the study patients, with stratification by tertile of CD34 þ KDR þ cell count. The three groups had no significant differences in clinical, biochemical or medication factors, except for a higher urea clearance (Kt/V) and greater prevalence of vascular disease history in the lowest CD34 þ KDR þ tertile. When we treated the CD34 þ KDR þ cell count as a continuous variable, it had no significant relationship with any of the baseline variables.
Follow-up
The median follow-up duration was 36 months (IQR: 23-52 months). We censored HD access thrombotic events until death, kidney transplantation or transfer to peritoneal dialysis or a non-study dialysis center. Two patients received kidney transplants. One of them experienced an HD access thrombotic event, but no systemic vascular event before transplantation; the other patient had neither an HD access nor systemic vascular thrombotic event before transplantation. No patients were transferred to peritoneal dialysis. Eight patients were transferred to other non-study dialysis centers; two had systemic vascular thrombotic events and five had HD access thrombotic events before transfer.
Deaths
As in Table 2 , we stratified the causes of death by tertile of CD34 þ KDR þ cell count. During the follow-up period, 77 (29%) of the 269 patients died, and 48 of these deaths were due to non-cardiovascular causes. The most common cause of death was infection. The CD34 þ KDR þ cell count did not correlate with the incidence of all-cause death or non-cardiovascular death. Twenty-nine (38%) of the 77 patients deaths were due to cardiovascular events. There was a trend for a negative correlation between the CD34 þ KDR þ count tertile and cardiovascular death, but this was not statistically significant (P ¼ 0.16).
Thrombotic events
A total of 141 patients experienced thrombotic events. Overall thrombotic events were negatively associated with CD34 þ KDR þ cell count tertile (low: 61%; middle: 56%; high: 40%; P ¼ 0.02). Fifty patients experienced systemic vascular thrombosis, and there was a significant negative association between systemic vascular thrombotic events and CD34 þ KDR þ cell count tertile (low: 27%; middle: 18%; high: 10%; P ¼ 0.03). Table 2 also provides details of the pertinent thrombotic events in different vascular beds. One hundred and sixteen patients experienced at least one HD access thrombotic event, and there was a significantly negative correlation of HD access thrombotic events with CD34 þ KDR þ cell count tertile (low: 52%; middle: 46%; high: 36%; P ¼ 0.02). In agreement, Kaplan-Meier plots indicate that circulating EPC tertile is negatively associated with overall thrombotic events, systemic vascular thrombotic events and HD access thrombotic events (Figure 3) .
We further stratified patients by hs-CRP and history of vascular disease to eliminate confounding by these factors. The results show the same negative associations remained when stratified by either factor (Figure 4 ).
Univariate and multivariate Cox models
Univariate analysis indicates that systemic vascular thrombosis is significantly associated with age, diabetes, dyslipidemia, vascular disease history, Kt/V, serum albumin and hs-CRP, and negatively associated with CD34 þ KDR þ cell count and tertile (Table 3) . Univariate analysis also indicates that HD access thrombosis is associated with vascular disease history, hs-CRP and low CD34 þ KDR þ cell count and tertile (Table 3) .
We entered all parameters with P-values <0.1 from this univariate analysis into a multivariate analysis. The multivariate analysis indicates that low CD34 þ KDR þ cell count and tertile were significant and independent risk factors for systemic vascular thrombosis and HD access thrombosis (Table 4) .
D I S C U S S I O N
The results of this 3-year prospective study of HD patients indicate that an EPC deficiency, defined as a low level of circulating CD34 þ KDR þ cells, was significantly associated with systemic vascular thrombosis and HD access thrombosis. These novel findings implicate a probable role of EPC insufficiency in the mechanism(s) underlying the susceptibility of HD patients to thrombosis.
Thrombosis is a consequence of interactions among hemostasis, hypercoagulability and vascular injury. Vascular injury is more common in HD patients, not only because of their increased susceptibility to atherosclerotic vascular disease, but also because of the regular vascular access punctures and frequent endovascular procedures. There are limited studies of the role of vascular repair of thrombotic events in HD patients. Some research indicates that disruption of the endothelium is the primary event in the initiation of thrombosis, and that an intact endothelium has anti-platelet and anti-thrombotic properties [18] . It therefore seems reasonable to hypothesize that a delay in vascular repair can increase the risk of thrombosis. Animal studies showed that re-endothelialization of damaged vessels by circulating EPCs leads to development of a mechanical barrier for the thrombogenic subendothelial matrix [19] . Besides functioning as a mechanical barrier, a functional endothelium produces many substances with autocrine and paracrine activity that have roles in hemostasis and thrombosis [20] . A low EPC count is associated with endothelial dysfunction, and increases the risk of thrombosis through plaque progression, activation of inflammation and impairment of antiplatelet and fibrinolytic capacities [21, 22] . Human studies have indicated that circulating EPC count is a marker of vascular repair capacity and vascular health [12, 23] .
Thrombosis of an HD access, either a synthetic graft or a native fistula, is usually secondary to intimal hyperplasia at outflow veins [24, 25] . Re-endothelization and endothelial function affect the development of intimal hyperplasia. A deficiency of EPCs can delay re-endothelization and lead to persistent inflammation, thereby potentiating smooth muscle cell proliferation, extracellular matrix deposition and intimal hyperplasia [26] . The EPC-mediated restoration of a functional and intact endothelium can reduce inflammation, as well as smooth muscle proliferation and migration [21, 27] . A previous study reported an EPC deficiency in patients presenting with restenosis after coronary angioplasty [28] . Another study reported an EPC deficiency in patients presenting with early and frequent restenosis of HD vascular accesses after percutaneous angioplasty [17] . Consequently, development of intimal hyperplasia may contribute to the great number of thrombotic events in patients with EPC deficiency.
The adsorption of thrombin to fibrin clots affects the endothelium, and may also contribute to EPC recruitment. Recent findings reported recruitment of EPCs to resolve venous thrombi, where they function as a type of plastic stem cell and 
promote thrombus re-canalization and resolution [29] . Additionally, shear stress can promote prostacyclin secretion, thereby inhibiting secretion of plasminogen activator inhibitor-1 by EPCs and limiting thrombus expansion [30] . In contrast to healthy patients, a study of patients undergoing peritoneal dialysis showed that low EPC count was associated with vascular disease, but not traditional risk factors [15] . The findings of the present study suggest that a unique mechanism underlies the association of EPC depletion with thrombosis in HD patients. Previous investigations reported that the modality of dialysis affected EPC count via uremiarelated toxins, erythropoietin and history of vascular diseases. For example, a variety of uremic toxins alters the number and function of EPCs [14] . These factors also have deleterious effects on the vascular outcomes of uremic patients. Consequently, the negative association between EPC count and thrombotic events may derive from the combination of several factors on vascular function. Circulating EPC count may therefore reflect the combined effects of these multiple inhibitory factors, and provide a valuable predictor of thrombotic events in vivo [31] .
A low EPC count, in addition to increasing the risk of atherosclerosis and thrombophilia, may be an alternative mechanism causing thrombotic events in HD patients. A variety of treatments, including pharmacological therapy, cellular therapy and stent-based therapy, may modulate the number and function of EPCs and facilitate vascular repair [27, 32] . Accordingly, animal studies with thrombosis models, in which there is modulation of the number and/or function of EPCs, may help to clarify the pathogenic role of EPCs in vascular thrombosis.
There were some limitations of the present study. First, this study had a moderate sample size and an observational design. Second, the findings reflect a single center experience of a racially homogeneous cohort, and may not be applicable to other populations. Third, no definition of EPC is universally accepted. KDR is not exclusively a marker of the EPCs, and hematopoietic stem cells and circulating mature endothelial cells also express this receptor [33] . Various methods to identify specific types of EPCs have recently become available, but were not available during conduct of this study.
The findings of the present study of HD patients indicate that a low circulating CD34 þ KDR þ cell count is associated with overall vascular thrombosis, systemic vascular thrombosis and HD access thrombosis. These associations are independent of clinical, biochemical or dialysis-related factors. Further studies are needed to determine whether EPC count can serve as a clinical marker and/or a therapeutic target of thrombotic events in HD patients.
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